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Several clinical studies have investigated the potential beneﬁts of endothelin receptor
antagonism in chronic pathologies such as diabetic kidney disease. However, ﬂuid retention
and edema have been identiﬁed as major side effects of endothelin receptor antagonists.
In the present study we hypothesized that avosentan which was described as a predomi-
nant ETA receptor antagonist would produce ﬂuid retention at high concentrations where
non-speciﬁc blockade of ETB receptors may occur. Incremental doses of the predominant
ETA receptor antagonist SPP301 (0.003; 0.03; 3mg/kg) were administered intravenously
to anesthetized Sprague-Dawley rats undergoing saline diuresis. Diuresis, glomerular ﬁltra-
tion rate, and blood pressure (BP) were monitored. SPP301 decreased urine output (5.6;
34.8; 58.8% decrease from vehicle) and fractional excretion of water (5.7; 31.7; 56.4%
decrease from vehicle) in a concentration-dependent manner. Glomerular ﬁltration rate
was unchanged while BP was reduced by 10mmHg only by the highest dose of SPP301.
Administration of the ETB selective receptor antagonist BQ-788 (3mg/kg) following SPP301
3mg/kg did not further decrease urine output or water excretion and was without effect
on glomerular ﬁltration rate. These data indicate that increasing concentrations of SPP301
may also block ETB receptors and cause antidiuresis. This effect could explain why ﬂuid
retention and edema occur during treatment with predominant ETA receptor blockers.
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INTRODUCTION
Endothelin-1 (ET-1) is a 21 amino acid peptide derived from
the vascular endothelium that has potent vasoactive properties
(Yanagisawa et al., 1988). ET-1 induces its effect by acting on
endothelinA and B receptors (ETA and ETB). Chronically elevated
ET-1 is involved in the pathophysiology of pulmonary arterial
hypertension, heart failure, systemic hypertension, renal dysfunc-
tion, and atherosclerosis (Haynes andWebb, 1998; Schneider et al.,
2007). Elevated plasma levels of ET-1 can be found in several
pathological states, including diabetes mellitus (De Mattia et al.,
1998; Bruno et al., 2002). The discovery of several compounds
acting as endothelin receptor antagonists has prompted research
toward their use in clinical practice (Anand et al., 2004; Packer
et al., 2005; McMurray et al., 2007).
Avosentan (SPP301) is a predominant ETA receptor antagonist
which was in development for the treatment of diabetic nephropa-
thy (Mann et al., 2010). Administration of SPP301 on top of stan-
dard care [including angiotensin-converting enzyme inhibitors
(ACEIs) or high dose angiotensin receptor blockers (ARBs)] has
been shown to result in a clinically relevant decrease in proteinuria
in patients with diabetic nephropathy. In the Randomized,Double
Blind,PlaceboControlled,ParallelGroupStudy toAssess theEffect
of the Endothelin Receptor Antagonist Avosentan on Time to
Doubling of Serum Creatinine, End Stage Renal Disease or Death
in PatientsWith Type 2DiabetesMellitus, andDiabeticNephropa-
thy (ASCEND) study, 50% of patients with diabetic nephropathy
and well-controlled blood pressure (BP) showed a 40–50% reduc-
tion in proteinuria with the addition of SPP301 to standard care
(Mann et al., 2010). However, the ASCEND trial was stopped due
to the adverse effects of SPP301. The most commonly reported
adverse effects were consistent with those previously reported for
the endothelin receptor antagonist class; namely edema, headache,
and anemia (Mann et al., 2010). Edema appears to be dose-related
and occurs more frequently with SPP301 than standard care alone.
Inpatientswith renal failure,SPP301 can aggravate existing edema.
ETA receptors are mainly localized in vascular smooth mus-
cle, vasa recta, and arcuate arteries and glomerulus (mesangial
cells and podocytes) and their stimulation or activation induce
vasoconstriction, salt and water retention, vascular proliferation,
inﬂammation, and ﬁbrosis (Jandeleit-Dahm and Watson, 2012).
There is now large evidence that ETA endothelin receptor blockade
confers renoprotection in several progressive renal disorders (Dav-
enport andMaguire, 2011;Gagliardini et al., 2011; Jandeleit-Dahm
and Watson, 2012). Preclinical and clinical data demonstrates that
of ETA receptor blockade is protective in chronic kidney dis-
ease through several effects including vasodilation, attenuation
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of proteinuria, increase of diuresis and natriuresis, inhibition of
inﬂammation, oxidative stress, and ﬁbrosis (Dhaun et al., 2011;
Jandeleit-Dahm and Watson, 2012). ETB receptors are expressed
in vascular and glomerular endothelial cells, mesangial cells, con-
voluted tubules and collecting duct epithelial cells, and their stim-
ulation or activation cause vasodilation, increase sodium excre-
tion, and inhibit vascular proliferation, inﬂammation, and ﬁbrosis
(Schneider et al., 2007). Recent data indicate that renal ETB recep-
tor antagonismor knockoutmay cause sodium retention (Ge et al.,
2006; Guo and Yang, 2006). Furthermore, ETB receptor deﬁciency
is associated with renal injury and an impaired ability to excrete a
sodium load (Ohkita et al., 2005). Thus, compoundswith predom-
inant selectivity against ETA receptorsmay produce ﬂuid retention
at concentrations where non-speciﬁc blockade of ETB receptors
may occur.
The objectives of our study were to (1) test the hypothesis that
the ETA receptor antagonist SPP301 at high concentrations may
cause ﬂuid retention, and (2) identify the concentration of SPP301
that inhibits ETB receptor-mediated effects and consequently leads
to acute ﬂuid retention in anesthetized rats. It is thought that
SPP301 at highdosesmay antagonize the ETB receptors and induce
ﬂuid retention.
MATERIALS AND METHODS
All procedures complied with guidelines from the American Phys-
iological Society, and the study was approved by a local review
board.
RAT STRAINS
Male Sprague-Dawley (SD) rats were obtained from Harlan, Indi-
anapolis (12–14weeks of age). Following acclimatization and
a health examination, rats were housed in groups of three in
standard cages with wire mesh tops and standardized softwood
bedding, synchronized to a 12-h light–dark cycle, at ambient tem-
perature 23± 2˚C. A standard rat diet and tap water were supplied
ad libitum.
STUDY DESIGN: EFFECT OF SPP301 ON RENAL EXCRETORY FUNCTION
The purpose of the experimental protocols was to examine the
acute effect of SPP301 on renal excretory function in a model of
volume expansion/saline diuresis (Guo and Yang, 2006).
After induction of anesthesia with Inactin (80mg/kg i.p.
thiobutabarbital sodium, Sigma Chemical, St. Louis, MO, USA),
SD rats were instrumentedwith catheters in: (1) the femoral artery
for measurement of BP by a pressure transducer connected to
a computerized data-acquisition system (PowerLab, ADInstru-
ments, Colorado Springs, CO, USA; Campos et al., 2004); (2)
the femoral vein for a constant infusion of artiﬁcial rat plasma
and to administer study drugs via bolus infusion; and (3) the
jugular vein for a constant infusion of 3H-inulin solution. A
catheter was also inserted in the left ureter for urine collection.
Artiﬁcial rat plasma [bovine serum albumin (BSA 2.5 g/100mL,
Sigma Chemical, St. Louis, MO, USA)+ bovine immunoglob-
ulins (2.5 g/100mL, Sigma Chemical, St. Louis, MO, USA) in
0.9% NaCl] was infused (12.5mL/kg/h for 45min, thereafter
1.5mL/kg/h) to maintain euvolemia throughout the experiment
(Reckelhoff et al., 1992).
Rats were divided into two groups of six animals each (Group
A and Group B). In both groups, Na2CO3 0.1M 1mL/kg was
administered as a vehicle during the baseline period.
In Group A, the selective ETB receptor antagonist BQ-788
(Sigma Chemical, St. Louis, MO, USA) was administered alone
as a 3-mg/kg dose by intravenous (i.v.) bolus in order to demon-
strate its effects on ETB receptors compared with the vehicle,
as described by Okada and Nishikibe (2002; Figure 1). Urine
and blood samples were collected over 20-min clearance peri-
ods during the baseline period and 10min after the i.v. bolus
administration. The protocol was to administer vehicle, followed
by BQ-788, then two more administrations of vehicle. The con-
centration of BQ-788 used was the highest concentration that
could be obtained by dissolution in the same vehicle as SPP301.
Since this concentration had the expected physiological effects
during single administration, it was used as ﬁnal positive con-
trol at the end of SPP301 administration experiments (Group B
of study).
Group B received increasing concentrations of SPP301 (0.003;
0.03; 3mg/kg, determined following completion of a dose-ranging
study; Speedel, Basel, Switzerland) administrated as an i.v. bolus
at 30-min intervals (Figure 1). The choice of bolus vs. infusion
was justiﬁed by the relatively long half-life of the compound (4 h)
compared to the length of our acute experimental protocol. It was
also preferred in order to minimize the length of time required for
loading and maintenance infusions. A 3-mg/kg dose of the selec-
tive ETB receptor antagonist BQ-788 was administered 30min
after the highest dose of SPP301 in order to test whether any
additional effects of blocking ETB receptors would be observed
(Okada and Nishikibe, 2002). Urine and blood samples were col-
lected over a total of ﬁve 20-min clearance periods during the
baseline period and 10min after i.v. bolus administration of each
study drug (Figure 1).
During each clearance period, urine was collected throughout
the 20-min clearance period and an arterial blood sample (two
hematocrit tubes – approximately 60μL) was collected from the
femoral artery catheter at themiddle of the clearanceperiod. Blood
samples were centrifuged and the resulting plasma used for further
analysis.
PLASMA AND URINE ELECTROLYTE MEASUREMENT
At the end of the experiment, sodium and potassium concentra-
tion in the urine was determined for each clearance period. The
rate of sodium and potassium excretion was calculated from these
values and the volume of urine per 20min as mEq/min. In addi-
tion, 3H-Inulin concentration in the plasma and urine samples
was measured (using a scintillation counter) and used to calcu-
late GFR. GFR for each clearance period was calculated as [Urine
volume (mL)/min]× [Urine concentration (cpm/mL)]/[Plasma
concentration (cpm/mL)] and expressed as mL/min.
STATISTICAL ANALYSIS
Statistical differences were determined with a one-way analy-
sis of variance (ANOVA), followed by Tukey’s range test for
dose-ascending studies using GraphPad software. p< 0.05 was
considered to be statistically signiﬁcant. Data are expressed as
means± SE.
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FIGURE 1 | Study design. Group A study design: i.v. administration of BQ-788 (3mg/kg) to anesthetized male SD rats undergoing saline diuresis. Group B
study design: i.v. administration of incremental doses of SPP301 (0.003; 0.03; 3mg/kg) followed by BQ-788 (3mg/kg) to anesthetized male SD rats undergoing
saline diuresis.
RESULTS
SELECTIVE BLOCKADE OF ETB RECEPTORS WITH BQ-788 AT
CONCENTRATIONS THAT DO NOT AFFECT GLOMERULAR
HEMODYNAMICS (GFR) LEADS TO ANTIDIURESIS
In this study, BQ-788 decreased urine output (115.4± 15 vs.
150.1± 21μL/min, p< 0.05) and fractional excretion of water
(5± 0.3 vs. 7.7± 1%, p< 0.05) compared with the vehicle, while
urinary excretion rates and plasma concentrations of sodium and
potassium were not altered. BQ-788 increased BP by 6± 1mmHg
(p< 0.05), but did not affect GFR (2.2± 0.1 vs. 1.9± 0.1mL/min,
p = 0.2) compared with the vehicle. These alterations returned
rapidly to normal values when vehicle was further administered,
demonstrating that the effects of BQ-788 are not only reversible
after acute administration but also provide a time-course effect of
vehicle.
SPP301 INDUCES ANTIDIURESIS AT HIGH CONCENTRATION
In this study, SPP301 decreased urine output and frac-
tional excretion of water in a concentration-dependent man-
ner (Figures 2A,B). Sodium excretion was initially increased
but returned to control values after the highest dose of SPP301
(Figures 2C,D). GFR was unchanged (Figure 3) while mean arter-
ial pressure (MAP)was reduced only by the highest dose (3mg/kg)
of SPP301 (Figure 4). Administration of BQ-788 (3mg/kg)
after SPP301 3mg/kg did not further decrease urine output or
water excretion (Figures 2A,B) and was without effect on GFR
(Figure 3). The data indicates that after the highest concentration
of SPP301, the effects persist beyond the 20-min clearance period,
when BQ-788 does not have an additional effect. This indicates
a full occupancy of ETB receptors by SPP301 before the BQ-788
administration. Hematocrit was signiﬁcantly (p< 0.05) decreased
by the higher doses of SPP301 (0.03; 3mg/kg) and with BQ-788
(Figure 5). Repetitive administration of the vehicle did not cause
the effects seen with SPP301 or BQ-788.
DISCUSSION
The present study demonstrates that SPP301 has antidiuretic
effects at high doses and causes subsequent hemodilution (indi-
cated by a decrease in hematocrit). These effects of SPP301 appear
independent of changes in GFR or BP. Following administration
of high dose (3mg/kg) SPP301, ETB receptor blockade with BQ-
788 did not cause further reductions in fractional water excretion
in the presence of SPP301.
Endothelin is known to have an important role in the regula-
tion of salt and water excretion by the kidney (Kohan et al., 2011).
For example, endothelin inhibits the action of vasopressin in the
isolated inner medullary collecting ducts (IMCD) of the kidneys,
an effect mediated by ETB receptors (Nadler et al., 1992; Edwards
et al., 1993). Medullary ETB receptor activation induces diuretic
andnatriuretic responses through anitric oxide synthase 1 (NOS1)
and cyclic guanylate monophosphate (cGMP) pathway (Nakano
et al., 2008). Intramedullary infusion of an ETB antagonist has
been shown to reduce urine ﬂow rate to 68% at 30min. Urinary
sodium excretion starts to decline only after 20–30min (Guo and
Yang, 2006). Collecting duct-speciﬁc knockout of ET-1 increases
urine concentrating effects of arginine vasopressin (AVP), while
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FIGURE 2 | Urine and sodium excretion measured by: (A) urine
output (μL/min); (B) fractional excretion of water (%); (C) urine
sodium output (μmol/min); and (D) fractional excretion of sodium
(%); in male SD rats treated with incremental doses of SPP301
(0.003; 0.03; 3mg/kg) followed by BQ-788 (3mg/kg). Fractional
excretion of water (percentage of water excreted by the kidney from the
total amount ﬁltered)=urine output/GFR. Fractional excretion of sodium
(percentage of Na+ excreted by the kidney from the total amount
ﬁltered)=urine Na+ output/[Plasma (Na+)×GFR]. *p<0.05 compared
with control (vehicle).
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FIGURE 3 | Glomerular filtration rate (mL/min) in male SD rats treated with incremental doses of SPP301 (0.003; 0.03; 3mg/kg) followed by BQ-788
(3mg/kg).
FIGURE 4 | Mean arterial pressure (mm Hg) in male SD rats treated with incremental doses of SPP301 (0.003; 0.03; 3mg/kg) followed by BQ-788
(3mg/kg). *p<0.05 compared with control (vehicle).
FIGURE 5 | Hematocrit (%) in male SD rats treated with incremental doses of SPP301 (0.003; 0.03; 3mg/kg) followed by BQ-788 (3mg/kg). *p<0.05
compared with control (vehicle).
collecting duct-speciﬁc ETA receptor knockout decreases renal
sensitivity to AVP (Ge et al., 2005). These ﬁndings suggest that
ETB receptor activation in the collecting duct has diuretic effects
and ETA receptor activation has antidiuretic effects. These effects
are mediated through altered renal sensitivity to the urinary
concentrating effects of AVP.
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ETB receptor activation is thought to play an important role in
the renal actions of somenaturally occurringhormones. For exam-
ple, relaxin has been localized in close proximity to the endothelin
receptors in the systemic and renal vasculature as well as in the
tubules of the kidney (Teichman et al., 2010). Relaxin binding to
its receptor, RXFP1, results in activation of the ETB receptor on
endothelial cells. Activation of the ETB receptor in the tubules
of the kidney by relaxin may inhibit sodium/potassium ATPase,
facilitating sodium and water secretion (Danielson et al., 1999;
Dschietzig et al., 2003; Bogzil and Ashton, 2009). Accordingly,
relaxin has been shown to increase clearance and urinary excretion
of sodium in preclinical rat studies (Bogzil et al., 2005). More-
over, in the Pre-RELAX acute heart failure study, dyspnea relief
correlated with BP reductions and increased weight loss in the
relaxin treatment groups, supporting the hypothesis that relaxin
may mediate natriuretic/diuretic effects (Teerlink et al., 2009).
Our results show that bolus i.v. administration of an ETB
receptor antagonist (BQ-788) reduces urine output and fractional
excretion of water within 30min of administration, but does not
signiﬁcantly alter urine sodium output or fractional excretion of
sodium. These data indicate that endogenous ET-1 has a tonic
diuretic effect mediated via renal ETB receptors and may explain
why ﬂuid retention occurs during treatment with non-selective
endothelin receptor blockers. Similarly, administration of a pre-
dominant ETA receptor antagonist (SPP301) dose-dependently
reduced urine output, fractional excretion of water and hemat-
ocrit. Since this effect does not appear to be mediated through
blockade of ETA receptors (which should promote diuresis),
SPP301 may produce dose-dependent antidiuresis through non-
speciﬁc blockade of ETB receptors. Moreover, since one of the
actions ascribed to the ETB receptor is the clearance of ET-1 from
circulation, its blockade may mediate an increased accessibility of
ET-1 to ETA receptors.
In addition to the induction of ﬂuid retention by renal mech-
anisms discussed here, it has been hypothesized that endothelin
receptor antagonists induce edema through increased capillary
permeability and consequent extravasation of ﬂuids. Results of
a related study in anesthetized bi-nephrectomized male Wis-
tar rats show that SPP301 blunted a decrease in hematocrit in
a concentration-dependent manner compared with a control,
with a plateau at 1μM (p< 0.05 for the trend). These obser-
vations suggest that SPP301 induces a concentration-dependent
vascular leakage of ﬂuid in this model (Maillard et al., 2008).
Together, these ﬁndings help to elucidate themechanisms bywhich
the predominant ETA receptor antagonist SPP301 induces ﬂuid
retention.
High doses of SPP301 (25, 50mg/day) have previously been
reported to result in ﬂuid overload and congestive heart failure
in patients with diabetic nephropathy (Mann et al., 2010). In a
follow-up explanatory mechanistic study in healthy subjects, a
dose-dependentmedian reduction in the fractional renal excretion
of sodium was found (up to 8.7% withSPP301 50mg); this reduc-
tion was paralleled by a dose-related increase in proximal sodium
reabsorption (Smolander et al., 2009). These clinical data together
with our preclinical results suggest thatSPP301 may cause non-
speciﬁc blockade of renal ETB receptors at high concentrations,
thereby causing ﬂuid retention.
The results of this study indicate that increasing concentrations
of SPP301 may block ETB receptors in addition to ETA receptors
and cause antidiuresis,which could explain the occurrence of ﬂuid
retention and the abolishment of beneﬁts mediated by ETA recep-
tor blockade observed in clinical trials (Smolander et al., 2009;
Mann et al., 2010). Further studies are needed to clarify whether
lower doses of ETA receptor blockers may be associated with fewer
renal adverse effects in clinical practice. In addition, further studies
may help to clarify the potential therapeutic value of ETB receptor
activation.
ETA receptor antagonists show promise in trials for the treat-
ment of chronic pathologies associated with tissue remodeling,
including diabetic kidney disease (Wenzel et al., 2009; Saleh et al.,
2011). However whilst demonstrating beneﬁts, these drugs also
have adverse effects on ﬂuid retention, leading to an altered risk–
beneﬁt ratio and limiting their clinical value (Kohan et al., 2011).
Indeed, efﬁcacy and safety are the main issues responsible for
the high attrition rate in phase III clinical drug development
(van Gool et al., 2010). Studying the complex mechanisms of
drug actions and corroborating them in an integrative physi-
ological context are necessary for a valid translation of med-
ical research into clinical practice. Our study represents a con-
crete example of translational research, demonstrating that drug
development is a two-way street requiring efﬁcient interactions
between preclinical and clinical research, and between pharma-
ceutical and academic scientists. These data, corroborated with
our colleagues’ data (Smolander et al., 2009), support further
investigation of the antiproteinuric effect of SPP301 at adjusted
doses.
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